Peter Ho

2.8k total citations · 1 hit paper
48 papers, 2.0k citations indexed

About

Peter Ho is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Ho has authored 48 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 21 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Ho's work include HER2/EGFR in Cancer Research (9 papers), Chromatin Remodeling and Cancer (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Peter Ho is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Chromatin Remodeling and Cancer (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Peter Ho collaborates with scholars based in United States, France and Netherlands. Peter Ho's co-authors include Wenle Xia, Lei-Hua Liu, Neil L. Spector, Malcolm A. Smith, Steven Hirschfeld, Richard Pazdur, Stephen J. Blakemore, Antoîne Italiano, Heike Keilhack and Scott Ribich and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Peter Ho

47 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

2018 451 citations Antoîne Italiano, Jean‐Charles Soria et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Peter Ho

Since Specialization

Citations

This map shows the geographic impact of Peter Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ho more than expected).

Fields of papers citing papers by Peter Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ho. The network helps show where Peter Ho may publish in the future.

Co-authorship network of co-authors of Peter Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ho. A scholar is included among the top collaborators of Peter Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ho. Peter Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study breakdown → 2018 ·The Lancet Oncology ·Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde, Jean‐Marie Michot, Carlo Lucchesi, Andréa Varga, Jean‐Michel Coindre, Stephen J. Blakemore, Alicia Clawson, Benjamin Suttle, Alice McDonald, Mark Woodruff, Scott Ribich, Eric Hedrick, Heike Keilhack, Blythe Thomson, Takashi Owa, Robert A. Copeland, Peter Ho, Vincent Ribrag	451
2	Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models 2017 ·Molecular Cancer Therapeutics ·Elayne Chan-Penebre, Kelli Armstrong, Allison E. Drew, Alexandra Grassian, Igor Feldman, Sarah K. Knutson, Kristy Kuplast‐Barr, Maria Roche, John Campbell, Peter Ho, Robert A. Copeland, Richard Chesworth, J. Joshua Smith, Heike Keilhack, Scott Ribich	127
3	Efficacy of levomilnacipran extended release in treating major depressive disorder 2017 ·Expert Opinion on Pharmacotherapy ·Renee‐Marie Ragguett, (unknown), Peter Ho, Roger S. McIntyre	2
4	Increased Intestinal Permeability in Relatives of Patients With Crohn’s Disease Is Not Associated With Small Bowel Ulcerations 2017 ·Clinical Gastroenterology and Hepatology ·Christopher Teshima, Karen J. Goodman, (unknown), Samina A. Turk, Wael El‐Matary, Rosica Valcheva, (unknown), Marilyn Gordon, Peter Ho, (unknown), Daniel J. Wong, Dina Kao, Jonathan B. Meddings, Hien Q. Huynh, Levinus A. Dieleman	26
5	Prostate cancer and antidepressants: A nationwide population-based nested case-control study 2017 ·Journal of Affective Disorders ·(unknown), Vincent Chin‐Hung Chen, Wei‐Che Chiu, (unknown), Peter Ho, Roger S. McIntyre, Mong‐Liang Lu, Shu‐I Wu	3
6	Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). 2017 ·Journal of Clinical Oncology ·Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoîne Italiano, Robin L. Jones, George D. Demetri, Stephen J. Blakemore, Alicia Clawson, Scott R. Daigle, Scott Ribich, Maria Roche, (unknown), Peter Ho, Gregory M. Coté	23
7	Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). 2016 ·Journal of Clinical Oncology ·Franck Morschhauser, Gilles Salles, Steven Le Gouill, John Radford, Pam McKay, Guillaume Cartron, (unknown), Maria Roche, Stephen J. Blakemore, Alice McDonald, Natalie M. Warholic, (unknown), Peter Ho, Vincent Ribrag	10
8	Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition 2015 ·Blood ·Neerav Shukla, Maureen M. O’Brien, Lewis B. Silverman, Melinda Pauly, Cynthia Wetmore, Mignon L. Loh, James A. Whitlock, Patrick A. Brown, Blythe Thomson, Stephen J. Blakemore, Scott R. Daigle, (unknown), Nigel J. Waters, (unknown), Richard P. Koche, Scott A. Armstrong, Peter Ho, Lia Gore	10
9	A proposal: a comprehensive platform to characterize tumors in Chinese and improve success in cancer drug discovery and development 2011 ·Chinese Journal of Cancer ·Pearl S. Huang, Peter Ho, Kang Zhang	0
10	A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose 2010 ·Cancer Chemotherapy and Pharmacology ·Kyle D. Holen, Chandra P. Belani, George Wilding, Suresh S. Ramalingam, Jennifer Volkman, Ramesh K. Ramanathan, Lakshmi Vasist, Carolyn J. Bowen, Jeffrey P. Hodge, Mohammed M. Dar, Peter Ho	60
11	A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors 2010 ·Investigational New Drugs ·Howard A. Burris, Suzanne F. Jones, Daphne Williams, Steven J. Kathman, Jeffrey P. Hodge, Lini Pandite, Peter Ho, Scott A. Boerner, Patricia LoRusso	52
12	Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer 2008 ·Journal of Clinical Oncology ·Anna Maria Storniolo, Mark D. Pegram, Beth Overmoyer, Paula Silverman, N. W. Peacock, Suzanne F. Jones, (unknown), Nikita Arya, Kevin M. Koch, Elaine Paul, Lini Pandite, Ronald A. Fleming, Peter F. Lebowitz, Peter Ho, Howard A. Burris	89
13	Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies 2007 ·Journal of Clinical Oncology ·Quincy S. Chu, Garry Schwartz, Johann S. de Bono, Deborah A. Smith, Kevin M. Koch, M. Versola, Lini Pandite, Nikita Arya, (unknown), Ronald A. Fleming, Peter Ho, Eric K. Rowinsky	48
14	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016 2004 ·Oncogene ·Wenle Xia, Lei-Hua Liu, Peter Ho, Neil L. Spector	197
15	Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies 2002 ·Cancer Biology & Therapy ·John R. Murren, Giuseppe Pizzorno, (unknown), (unknown), (unknown), (unknown), Walter J. McMurray, Barbara Burtness, Thomas Rutherford, Xin Li, Peter Ho, Alan C. Sartorelli	12
16	The Role of Imaging in the Development of Oncologic Agents 1999 ·The Journal of Clinical Pharmacology ·Anthony F. Shields, Peter Ho, John R. Grierson	6
17	Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) 1996 ·Investigational New Drugs ·Malcolm A. Smith, Peter Ho	12
18	Characterization of the defect in a variant of HL-60 promyelocytic leukemia cells with reduced transferrin receptor expression 1992 ·Somatic Cell and Molecular Genetics ·Kimiko Ishiguro, Peter Ho, Alan C. Sartorelli	4
19	Centriole ciliation and cell cycle variability during G₁ phase of BALB/c 3T3 Cells 1989 ·Journal of Cellular Physiology ·Peter Ho, Robert W. Tucker	24
20	Neuroendocrine (Merkel cell) carcinoma of the vulva 1988 ·Gynecologic Oncology ·Nader Husseinzadeh, Terrence Wesseler, Nancy J. Newman, (unknown), Peter Ho	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact